Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study : SIMPLICITY
SIMPLICITY (NCT01244750) was an observational study evaluating first-line (1 L) tyrosine kinase inhibitors (TKIs; dasatinib, nilotinib, imatinib) in patients with chronic myeloid leukemia in the chronic phase in routine clinical practice. At data cutoff (January 28, 2020), 810 prospective US patient...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
22 Jun 2025
|
| In: |
Leukemia and lymphoma
Year: 2025, Jahrgang: 66, Heft: 9, Pages: 1615-1624 |
| ISSN: | 1029-2403 |
| DOI: | 10.1080/10428194.2025.2495369 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1080/10428194.2025.2495369
|
| Verfasserangaben: | Michael J. Mauro, Rüdiger Hehlmann, Loretta A. Williams, Stuart L. Goldberg, Mauricette Michallet, Carlo Gambacorti-Passerini, Derek Tang, Irene S. DeGutis, Ali McBride, Lori Parsons, Monica Montelongo and Jorge E. Cortes |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1937613984 | ||
| 003 | DE-627 | ||
| 005 | 20251002094228.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 251002s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10428194.2025.2495369 |2 doi | |
| 035 | |a (DE-627)1937613984 | ||
| 035 | |a (DE-599)KXP1937613984 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Mauro, Michael J. |e VerfasserIn |0 (DE-588)141997265 |0 (DE-627)704116219 |0 (DE-576)327279605 |4 aut | |
| 245 | 1 | 0 | |a Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase |b a prospective, observational study : SIMPLICITY |c Michael J. Mauro, Rüdiger Hehlmann, Loretta A. Williams, Stuart L. Goldberg, Mauricette Michallet, Carlo Gambacorti-Passerini, Derek Tang, Irene S. DeGutis, Ali McBride, Lori Parsons, Monica Montelongo and Jorge E. Cortes |
| 264 | 1 | |c 22 Jun 2025 | |
| 300 | |b Diagramme | ||
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 02.10.2025 | ||
| 520 | |a SIMPLICITY (NCT01244750) was an observational study evaluating first-line (1 L) tyrosine kinase inhibitors (TKIs; dasatinib, nilotinib, imatinib) in patients with chronic myeloid leukemia in the chronic phase in routine clinical practice. At data cutoff (January 28, 2020), 810 prospective US patients were included/analyzed (dasatinib, 302; nilotinib, 264; imatinib, 244). Within 5 years, 95.4% of patients (dasatinib, 96.5%; nilotinib, 93.5%; imatinib, 95.9%) had major molecular response (BCR::ABL1 ≤ 0.1%), and 79.2% (dasatinib, 79.8%; nilotinib, 81.7%; imatinib, 75.9%) deep molecular response (MR4.5; BCR::ABL1 < 0.0032%) demonstrating major improvement during the study period. Of 734 patients followed for 5 years, 5-year overall survival rate was 89.8% (dasatinib, 92.9%; nilotinib, 88.6%; imatinib, 87.0%); similar to that in randomized studies. Patients who switched treatment had a poorer outcome regardless of TKI, indicating that non-kinase domain mutations may play a role. Despite missing data on outcomes in routine care, these results demonstrate excellent response and survival rates. | ||
| 650 | 4 | |a Chronic-phase chronic myeloid leukemia | |
| 650 | 4 | |a molecular response | |
| 650 | 4 | |a observational study | |
| 650 | 4 | |a overall survival | |
| 650 | 4 | |a routine care | |
| 650 | 4 | |a SIMPLICITY | |
| 650 | 4 | |a treatment switch | |
| 650 | 4 | |a tyrosine kinase inhibitor | |
| 700 | 1 | |a Hehlmann, Rüdiger |d 1941- |e VerfasserIn |0 (DE-588)1037003489 |0 (DE-627)751737879 |0 (DE-576)390939463 |4 aut | |
| 700 | 1 | |a Williams, Loretta A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goldberg, Stuart L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Michallet, Mauricette |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gambacorti-Passerini, Carlo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tang, Derek |e VerfasserIn |4 aut | |
| 700 | 1 | |a DeGutis, Irene S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a McBride, Ali |e VerfasserIn |4 aut | |
| 700 | 1 | |a Parsons, Lori |e VerfasserIn |4 aut | |
| 700 | 1 | |a Montelongo, Monica |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cortes, Jorge E. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia and lymphoma |d London [u.a.] : Taylor & Francis Group, 1989 |g 66(2025), 9, Seite 1615-1624 |h Online-Ressource |w (DE-627)324746237 |w (DE-600)2030637-4 |w (DE-576)099718170 |x 1029-2403 |7 nnas |a Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase a prospective, observational study : SIMPLICITY |
| 773 | 1 | 8 | |g volume:66 |g year:2025 |g number:9 |g pages:1615-1624 |g extent:10 |a Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase a prospective, observational study : SIMPLICITY |
| 856 | 4 | 0 | |u https://doi.org/10.1080/10428194.2025.2495369 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20251002 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 1037003489 |a Hehlmann, Rüdiger |m 1037003489:Hehlmann, Rüdiger |d 60000 |e 60000PH1037003489 |k 0/60000/ |p 2 | ||
| 999 | |a KXP-PPN1937613984 |e 477982723X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"family":"Mauro","roleDisplay":"VerfasserIn","display":"Mauro, Michael J.","role":"aut","given":"Michael J."},{"role":"aut","display":"Hehlmann, Rüdiger","given":"Rüdiger","family":"Hehlmann","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Williams","display":"Williams, Loretta A.","role":"aut","given":"Loretta A."},{"display":"Goldberg, Stuart L.","role":"aut","given":"Stuart L.","roleDisplay":"VerfasserIn","family":"Goldberg"},{"given":"Mauricette","role":"aut","display":"Michallet, Mauricette","family":"Michallet","roleDisplay":"VerfasserIn"},{"display":"Gambacorti-Passerini, Carlo","role":"aut","given":"Carlo","roleDisplay":"VerfasserIn","family":"Gambacorti-Passerini"},{"role":"aut","display":"Tang, Derek","given":"Derek","roleDisplay":"VerfasserIn","family":"Tang"},{"family":"DeGutis","roleDisplay":"VerfasserIn","given":"Irene S.","role":"aut","display":"DeGutis, Irene S."},{"roleDisplay":"VerfasserIn","family":"McBride","given":"Ali","display":"McBride, Ali","role":"aut"},{"roleDisplay":"VerfasserIn","family":"Parsons","display":"Parsons, Lori","role":"aut","given":"Lori"},{"roleDisplay":"VerfasserIn","family":"Montelongo","role":"aut","display":"Montelongo, Monica","given":"Monica"},{"family":"Cortes","roleDisplay":"VerfasserIn","given":"Jorge E.","display":"Cortes, Jorge E.","role":"aut"}],"physDesc":[{"noteIll":"Diagramme","extent":"10 S."}],"name":{"displayForm":["Michael J. Mauro, Rüdiger Hehlmann, Loretta A. Williams, Stuart L. Goldberg, Mauricette Michallet, Carlo Gambacorti-Passerini, Derek Tang, Irene S. DeGutis, Ali McBride, Lori Parsons, Monica Montelongo and Jorge E. Cortes"]},"relHost":[{"pubHistory":["1.1989/90 -"],"recId":"324746237","part":{"pages":"1615-1624","year":"2025","extent":"10","volume":"66","issue":"9","text":"66(2025), 9, Seite 1615-1624"},"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"dateIssuedDisp":"1989-","publisherPlace":"London [u.a.] ; London [u.a.]","dateIssuedKey":"1989","publisher":"Taylor & Francis Group ; Informa Healthcare"}],"id":{"eki":["324746237"],"zdb":["2030637-4"],"issn":["1029-2403"]},"title":[{"title_sort":"Leukemia and lymphoma","title":"Leukemia and lymphoma"}],"disp":"Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase a prospective, observational study : SIMPLICITYLeukemia and lymphoma","note":["Gesehen am 08.09.15"]}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"22 Jun 2025","dateIssuedKey":"2025"}],"language":["eng"],"recId":"1937613984","title":[{"title_sort":"Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase","title":"Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase","subtitle":"a prospective, observational study : SIMPLICITY"}],"id":{"eki":["1937613984"],"doi":["10.1080/10428194.2025.2495369"]},"note":["Gesehen am 02.10.2025"]} | ||
| SRT | |a MAUROMICHAFIVEYEARMO2220 | ||